Concepedia

Margaret McJannett

MM

Statistics

Publications

19

Citations

3.8K

H-Index

16

Active since

2003

Affiliations

Australian and New Zealand Urogenital and Prostate Cancer Trials Group(Current)

The University of Sydney

Monash University

National Health and Medical Research Council

Eastern Health

Margaret McJannett is an author at Australian and New Zealand Urogenital and Prostate Cancer Trials Group specializing in oncology, medicine, and prostate cancer.

ORCID

Publications per year

2003–2025

19

Publications

19

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

, , +17

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

, , +12

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 266 citations

, , +16

TheraP: a randomized phase 2 trial of <sup>177</sup> Lu‐ <scp>PSMA</scp> ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <scp>ANZUP</scp> 1603)

Michael S. Hofman, Louise Emmett, John Violet et al. · British Journal of Urology · 2019 · 162 citations · Full text

, , +17

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2024 · 155 citations

, , +12

1–5 of 19